OptiNose US, Inc., 1020 Stony Hill Road, Suite 300, Yardley, PA 19067Letter Agreement • January 31st, 2023 • OptiNose, Inc. • Pharmaceutical preparations • Pennsylvania
This letter agreement (this “Letter Agreement”) sets forth then terms and conditions under which OptiNose US, Inc. (the “Company”) hereby engages you Peter K. Miller (“you” or “Consultant” as a consultant to the Company. By signing this letter, you accept this engagement subject to these terms and conditions.
SEPARATION AGREEMENT AND GENERAL RELEASESeparation Agreement and General Release • January 31st, 2023 • OptiNose, Inc. • Pharmaceutical preparations • Delaware
THIS SEPARATION AGREEMENT AND GENERAL RELEASE (“Agreement”) is made and entered into between Peter K. Miller (“you”) and OptiNose US, Inc. (“Optinose” or the “Company”) to confirm the terms of your separation from employment and to settle, release and discharge, with prejudice, any and all claims you have or may have against the Released Parties (defined in Paragraph 3(a) below), including but not limited to those arising or which may be arising out of your employment with and/or your separation of employment from the Company. In consideration of the mutual commitments set forth in this Agreement, and intending to be legally and forever bound, you and the Company therefore understand and agree as follows:
AMENDED AND RESTATED EMPLOYMENT AGREEMENTEmployment Agreement • January 31st, 2023 • OptiNose, Inc. • Pharmaceutical preparations • Pennsylvania
This AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the “Agreement”) is entered into on January 30, 2023 (the “Effective Date”), by and between OptiNose US, Inc., a Delaware corporation (“OptiNose US” and the “Company”), and Ramy A. Mahmoud (“Executive”).
